ERBB2 and inflammatory breast carcinoma: The ORR was 37% (95% CI, 24.3–51.3%), with a median duration of response of 10.4 months, in a refractory HER-2/positive IBC patients' cohort and a heavily pretreated cohort of HER2-low IBC patients, which corresponds to our study results.